Trials / Not Yet Recruiting
Not Yet RecruitingNCT06364501
Phase 1 Trial of KH801
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Anti-tumor Activity of KH801 Injection in Patients With Advanced Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (estimated)
- Sponsor
- Beijing Kanghong Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
KH801 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Or 0.9% sodium chloride Injection. This study is expected to include a total of approximately 17-42 participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KH801 | KH801 is an injection solution |
Timeline
- Start date
- 2024-09-01
- Primary completion
- 2026-05-01
- Completion
- 2030-05-01
- First posted
- 2024-04-15
- Last updated
- 2024-08-07
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06364501. Inclusion in this directory is not an endorsement.